# Patient Workup for the Treatment of Hepatitis C

#### **Dr Astrid Arellano MBBS FRACP**

Infectious Diseases Physician Director Perth Infectious Diseases Senior Consultant Fiona Stanley Hospital and WA TB Control Program




#### Outline

- Hepatitis C overview
- New Treatments
- Assessment of patients and workup for treatment

### Hepatitis C


- Major PH challenge- 75% chronic disease
- 20-30 years on- 1/3 develop cirrhosis and HCC
- Notifiable disease- 75-85% HCV infected diagnosed
- Decreased new cases BUT complications increasing



#### Thursday, 1 September 16

#### Burden of Disease

- Only I-2% treatment uptake (toxicity)
- 2013 most mild liver fibrosis (6% or 13,000)
- 2030 liver fibrosis will triple (38,000) with
  >2000 HCC and >1700 liver deaths



Australian recommendations for the management of Hepatitis C infection: A consensus statement 2016, Gastroneterological Society of Australia


#### Timeline of Hepatitis C



### Directly Acting Antivirals- DAAs

- Target multiple steps in HCV replication
- Highly effective
- Safe
- Short term treatments- 12 weeks even cirrhosis

#### DAAs mechanisms of action



#### Hep C Treatment Choices

Pintt btype	No Previous Treatment (naïve)		Previously Received Treatment (experienced)		
стре	No cirrhosis	With cirrhosis	No cirrhosis	With cirrhosis	
1 a/b	Ledipasvir/sofosbuvir [8 or 12 weeks]	Ledipasvir/sofosbuvir [12 weeks] or Sofosbuvir and Peg-Interferon alfa-2a/ribavirin [12 weeks]	Ledipasvir/sofosbuvir [12 weeks] or Sofosbuvir and Peg-Interferon alfa-2a/ribavirin [12 weeks]	Ledipasvir/sofosbuvir [24 weeks] or Sofosbuvir and Peg-Interferon alfa-2a/ribavirin [12 weeks]	
1 a/b	Daclatasvir and sofosbuvir [12 weeks]	Daclatasvir and sofosbuvir and ribavirin [12 weeks] or Daclatasvir and sofosbuvir [24 weeks]	Daclatasvir and sofosbuvir [12 or 24 weeks]	Daclatasvir and sofosbuvir and ribavirin [12 weeks] or Daclatasvir and sofosbuvir [24 weeks]*	
1a	Paritaprevir-ritonavir,	Paritaprevir-ritonavir,	Paritaprevir-ritonavir,	Paritaprevir-ritonavir,	
	ombitasvir, dasabuvir and	ombitasvir, dasabuvir and	ombitasvir, dasabuvir and	ombitasvir, dasabuvir and	
	ribavirin (12 weeks)	ribavirin (12 weeks)	ribavirin (12 weeks)	ribavirin (12 or 24 weeks)	
1b*	Paritaprevir-ritonavir,	Paritaprevir-ritonavir,	Paritaprevir-ritonavir,	Paritaprevir-ritonavir,	
	ombitasvir and dasabuvir	ombitasvir and dasabuvir	ombitasvir and dasabuvir	ombitasvir and dasabuvir	
	(12 weeks)	(12 weeks)	(12 weeks)	(12 weeks)	
2	Sofosbuvir and ribavirin	Sofosbuvir and ribavirin	Sofosbuvir and ribavirin	Sofosbuvir and ribavirin	
	[12 weeks]	[12 weeks]	[12 weeks]	[12 weeks]	
3	Daclatasvir and sofosbuvir	Daclatasvir and sofosbuvir	Daclatasvir and sofosbuvir	Daclatasvir and sofosbuvir	
	[12 weeks]	[24 weeks]	[12 weeks]	[24 weeks]	
	or	or	or	or	
	Sofosbuvir and ribavirin	Sofosbuvir and ribavirin	Sofosbuvir and ribavirin	Sofosbuvir and ribavirin	
	[24 weeks]	[24 weeks]	[24 weeks]	[24 weeks]	
4, 5, 6	Sofosbuvir and Peg-Interferon	Sofosbuvir and Peg-Interferon	Sofosbuvir and Peg-Interferon	Sofosbuvir and Peg-Interferon	
	alfa-2a/ribavirin	alfa-2a/ribavirin	alfa-2a/ribavirin	alfa-2a/ribavirin	
	[12 weeks]	[12 weeks]	[12 weeks]	[12 weeks]	

<u>http://www.gesa.org.au/professional.asp?cid=77&id=454</u> <u>http://www.hepatitisaustralia.com/hepatitis-c-facts/treatment-for-hep-c</u>.

- Could it be Hep C?
- Confirm the diagnosis
- Treat
- Refer for treatment
- Follow up

#### • Could it be Hep C?

- Patient request, abnormal LFTs, doctor concern
- Risk factors\*

#### Table 1. High-risk populations for hepatitis C virus (HCV) infection

- People who inject drugs or who have ever injected drugs
- Sex workers
- People in custodial settings
- People with tattoos or body piercing.
- People who received a blood transfusion or organ transplant before 1990
- Children born to HCV-infected mothers
- Sexual partners of an HCV-infected person.
- People infected with human immunodeficiency virus or hepatitis B virus
- People with evidence of liver disease (persistently elevated alanine aminotransferase level)
- People who have had a needlestick injury
- Migrants from high-prevalence regions (Egypt, Pakistan, Mediterranean and Eastern Europe, Africa and Asia)

- Confirm the diagnosis
- Order Hepatitis C Antibody test
- Order Hepatitis C RNA PCR

\*Consent needs to include reasons for testing, meaning of a positive test, positive results in person

- Hep C Ab positive
- HCV RNA PCR not detected
- Cleared infection (only 25%)

- Hep C Ab positive
- HCV RNA PCR detected (>6 months)
- Chronic Hepatitis C infection

- Follow up and/or referral?
- Aim should be to treat
- Assess and treat
- Assess and refer

# History

- Estimate duration of HCV infection
- Previous HCV treatment
- Factors for liver disease progression: alcohol intake, marijuana, co-infection with HIV or HBV, diabetes, obesity
- IHD/cardiovascular risk factors (ribavirin)
- HAV and HBV vaccination
- Ongoing risk behaviours/education about reducing transmission/reinfection

#### Medications



#### HEP Drug Interaction Checker

Access our comprehensive, user-friendly, free drug interaction charts. Providing clinically useful, reliable, up-to date, evidence-based information

-	Potential Interaction  No Interaction Expected  Potential Interaction  No Interaction Expected					
	•		•	•		•
	•	•		٠	٠	
	•	•	•	•	•	•
	•	•	•			•
	•	•	•	•	•	•
	•	•			•	•
						•

#### • Prescription

- Over the counter
- Illicit

#### http://www.hep-druginteractions.org/

## Physical Exam

- Features of cirrhosis: hard liver edge, spider naevi, gynaecomastia
- Decompensation: jaundice, ascites, oedema, bruising, muscle wasting, encephalopathy
- Body weight and BMI

# Virology

- Further Viral-related tests
  - HCV genotype (\*treatment regimen)
  - HCV RNA quantitative (viral load)
  - HBV (HbsAg, anti-HBc, anti-HBs), HAV, HIV serology

## Investigations

- FBP, LFTs, Urea and electrolytes, eGFR, INR
- Pregnancy test
- Liver fibrosis assessment
  - Elastography
  - Biomarkers (APRI, Hepascore, ELF test)
- Liver ultrasound
- Electrocardiogram if ribavirin therapy planned, >50 years and cardiac risk factors

### Liver fibrosis assessment

- Cirrhosis affects treatment choice and duration
- Requirement for PBS Authority
- Patients with cirrhosis require lifelong HCC and portal hypertension surveillance

### Factors associated with progression to liver disease in chronic HCV

Age at acquisition of infection (>40 years)

Heavy alcohol intake (>40g/day)

Male gender

Longer duration of infection

Moderate-severe fibrosis on baseline Elastography

Co-infection with HBV or HIV

Obesity

NB Viral load is not associated with progression

### Liver fibrosis assessment

- Peripheral stigmata of chronic liver disease
- Portal hypertension: splenomegaly, thrombocytopaenia
- Low albumin, raised bilirubin, raised INR

### Liver fibrosis assessment

- Liver biopsy is rarely performed
- Non-invasive tests such as Elastography are now routine
- These techniques outperform biomarkers for the assessment of fibrosis
  - \*Hepascore/APRI/others
- No method is totally accurate
- Patients with cirrhosis need endoscopy

#### Cirrhosis

- Should be referred to a specialist
- Need evaluation for decompensation
- Need endoscopy
- Certain DAAs are contraindicated in this group because of hepatic toxicity (NS3-PI)

#### Other considerations

- Adherence
- Stable psychiatric
- Stable injecting drug use
- No fibrosis- alcohol acceptable 2 std/day
- Cirrhosis- total alcohol abstinence

#### Hep C Treatment Choices

Pintt btype	No Previous Treatment (naïve)		Previously Received Treatment (experienced)		
ытворре	No cirrhosis	With cirrhosis	No cirrhosis	With cirrhosis	
1 a/b	Ledipasvir/sofosbuvir [8 or 12 weeks]	Ledipasvir/sofosbuvir [12 weeks] or Sofosbuvir and Peg-Interferon alfa-2a/ribavirin [12 weeks]	Ledipasvir/sofosbuvir [12 weeks] or Sofosbuvir and Peg-Interferon alfa-2a/ribavirin [12 weeks]	Ledipasvir/sofosbuvir [24 weeks] or Sofosbuvir and Peg-Interferon alfa-2a/ribavirin [12 weeks]	
1 a/b	Daclatasvir and sofosbuvir [12 weeks]	Daclatasvir and sofosbuvir and ribavirin [12 weeks] or Daclatasvir and sofosbuvir [24 weeks]	Daclatasvir and sofosbuvir [12 or 24 weeks]	Daclatasvir and sofosbuvir and ribavirin [12 weeks] or Daclatasvir and sofosbuvir [24 weeks]*	
1a	Paritaprevir-ritonavir,	Paritaprevir-ritonavir,	Paritaprevir-ritonavir,	Paritaprevir-ritonavir,	
	ombitasvir, dasabuvir and	ombitasvir, dasabuvir and	ombitasvir, dasabuvir and	ombitasvir, dasabuvir and	
	ribavirin (12 weeks)	ribavirin (12 weeks)	ribavirin (12 weeks)	ribavirin (12 or 24 weeks)	
1b*	Paritaprevir-ritonavir,	Paritaprevir-ritonavir,	Paritaprevir-ritonavir,	Paritaprevir-ritonavir,	
	ombitasvir and dasabuvir	ombitasvir and dasabuvir	ombitasvir and dasabuvir	ombitasvir and dasabuvir	
	(12 weeks)	(12 weeks)	(12 weeks)	(12 weeks)	
2	Sofosbuvir and ribavirin	Sofosbuvir and ribavirin	Sofosbuvir and ribavirin	Sofosbuvir and ribavirin	
	[12 weeks]	[12 weeks]	[12 weeks]	[12 weeks]	
3	Daclatasvir and sofosbuvir	Daclatasvir and sofosbuvir	Daclatasvir and sofosbuvir	Daclatasvir and sofosbuvir	
	[12 weeks]	[24 weeks]	[12 weeks]	[24 weeks]	
	or	or	or	or	
	Sofosbuvir and ribavirin	Sofosbuvir and ribavirin	Sofosbuvir and ribavirin	Sofosbuvir and ribavirin	
	[24 weeks]	[24 weeks]	[24 weeks]	[24 weeks]	
4, 5, 6	Sofosbuvir and Peg-Interferon	Sofosbuvir and Peg-Interferon	Sofosbuvir and Peg-Interferon	Sofosbuvir and Peg-Interferon	
	alfa-2a/ribavirin	alfa-2a/ribavirin	alfa-2a/ribavirin	alfa-2a/ribavirin	
	[12 weeks]	[12 weeks]	[12 weeks]	[12 weeks]	

<u>http://www.gesa.org.au/professional.asp?cid=77&id=454</u> <u>http://www.hepatitisaustralia.com/hepatitis-c-facts/treatment-for-hep-c</u>.

#### Treatment monitoring

- Intense monitoring not necessary
- Non-cirrhotic: baseline and FBP/LFTs/ adherence/side effects/cardiac risk factors at week 4.
- Cirrhotic: baseline and FBP/LFTs/adherence/ side effects/cardiac risk factors at week 4, 8 and 12.
- HCV RNA PCR at week 12 and 24
- Poor response: non-adherence, reinfection

# Monitoring after SVR

#### B. Monitoring after SVR

SVR, no cirrhosis and normal LFT results (males, ALT < 30 U/L; females, ALT < 19 U/L):

Patients who are cured do not require clinical follow-up for HCV

SVR and abnormal LFT results (males, ALT  $\ge$  30 U/L; females, ALT  $\ge$  19 U/L):

 Patients with persistently abnormal LFT results require evaluation for other liver diseases and should be referred for gastroenterology review. Investigations to consider include: fasting glucose level, fasting lipid levels, iron studies, ANA, ASMA, anti-LKM antibodies, total IgG and IgM, AMA, coeliac serology, copper level, caeruloplasmin level and 0-1-antitrypsin level

SVR, cirrhosis:

- Patients with cirrhosis require long-term monitoring and should be enrolled in screening programs for:
  - hepatocellular carcinoma liver ultrasound ±serum ü-fetoprotein level
  - oesophageal varices gastroscopy
  - osteoporosis dual emission x-ray absorptiometry

EOT = end of treatment. SVR = sustained virological response at least 12 weeks after treatment (cure). FBE = full blood examination. LFT = liver function test. INR = international normalised ratio. PCR = polymerase chain reaction. ALT = alanine aminotransferase. ANA = antinuclear antibodies. ASMA = anti-smooth muscle antibodies. LKM = liver-kidney microsome. AMA = anti-mitochondrial antibody.

> Australian recommendations for the management of Hepatitis C infection: A consensus statement 2016, Gastroneterological Society of Australia



Home > Site pages > Managing hepatitis C in primary care

Navigation 🔳 👻	N
A Home	T
Antimicrobial modules	tre
Blood Pressure: Measure,	ch
manage, monitor	si
Case studies	es
Chronic abdominal pain in	pe
adults - when is imaging	m
Dealing with uncertainty: a	a
diagnostic approach to	ge
Demystifying bioequivalence	of
Drug misuse: implications for	
pharmacists	Vi
Get it right! Taking a Best	Та
Possible Medication Hi	
Managing hepatitis C in	0
primary care	C
Medical tests	-
Medication safety	C
National Inpatient Medication	
~ · ·	

#### Managing hepatitis C in primary care

This module will provide you with training in the diagnosis, treatment and ongoing management of people with chronic hepatitis C infection. Hepatitis C (HCV) remains a significant public health issue in Australia and GPs are an essential part of the management team, from identifying people who may be at risk of infection to diagnosis and monitoring of liver disease. In addition, with the new directacting antiviral (DAA) agents now available on the PBS general schedule it is even more vital that GPs are aware of HCV treatment strategies.

View the learning outcomes.


Target audience: GPs Open to: GPs, Pharmacists, Nurses, Students

Cost: Free

CPD points: GPs - view details



#### http://learn.nps.org.au/mod/page/view.php?id=7278



#### Hepatitis C

The hepatitis C program comprises two modules spanning prevention and treatment strategies, along the continuum of care. Assessments are completed at the end of each module.







Module 1 Overview of hepatitis C, prevention and treatment strategies



Module 2 Assessment and management of hepatitis C along the continuum of care

#### http://hepatitis.ecu.edu.au/hepc/index.php

# Take Home Messages

- Think about Hep C in at risk groups and test
- Confirm the diagnosis
- Work up patients for treatment
- Treat (Educations Modules)
- Refer (Shared Care)
- Challenges: access to treatment, rapidly changing landscape of DAAs, pitfalls of therapy, developing models of care.

#### Thank you for listening!



Perth Infectious Diseases

6-8 Antony St, Palmyra WA 6157 <u>www.doctorastrid.com</u> 08 9319 3811 0421514653